City Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines, founded by John Maraganore (former CEO of Alnylam Pharmaceuticals) and a team of RNAi pioneers. The company's lead platform is based on cleavage-inducing tiny guide RNAs (cityRNAs) designed to improve potency and durability over first-generation siRNA therapeutics, with three programs in the pipeline targeting cardiometabolic and rare diseases.
Company Info
Funding & Investor Relations
None publicly disclosed; private RNAi platform company focused on pipeline development.
Upcoming Milestones & Key Dates
First IND filing for CTX-001 cardiometabolic program
Pipeline expansion update and potential Series B or strategic partnership
Clinical Development Pipeline
Recent News
City Therapeutics has closed a $99M financing round to advance its pipeline of three RNAi medicines, betting on a next-generation small interfering RNA platform that aims to improve potency and durability over current standards.
Leadership Team
Founder and Chief Executive Officer (former CEO of Alnylam Pharmaceuticals)
Chief Medical Officer
Chief Scientific Officer
Careers & Job Openings